Pramlintide: research

A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.

Also called: Symlin, SymlinPen, Pramlintide acetate, AC137, AC-0137, Tripro-amylin.

Amylin analogues · Short-acting amylin receptor agonist · Evidence: Approved drug.

51 completed, terminated or active registered studies were found; 15 planned, withdrawn or unknown-status records were excluded. Early unregistered trials make this a minimum.

Studies

Pramlintide dosage

Typical reported dose: Type 1 diabetes: starts at 15 mcg before meals, up to 60 mcg

  • Symlin label: type 1 diabetes: 15 mcg before each major meal, then 30 mcg before each major meal, then 45 mcg before each major meal, then 60 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 1 diabetes using mealtime insulin. (source)
  • Symlin label: type 2 diabetes: 60 mcg before each major meal, then 120 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 2 diabetes using mealtime insulin. (source)
  • Early trial: 30 mcg per meal: 30 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
  • Early trial: 100 mcg per meal: 100 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
  • Early trial: 300 mcg per meal: 300 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
  • 30 mcg four times daily: 30 mcg subcutaneously four times daily four times daily, under the skin. Studied in a trial. Studied in: Insulin-using adults with type 2 diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Pramlintide side effects and risks

Reported side effects

  • Nausea: Type 1 label pool: 48% versus 17% placebo; type 2: 28% versus 12%., moderate. Persistent nausea needs clinician review; treatment may need to be reduced or stopped. (source)
  • Vomiting: Type 1: 11% versus 7% placebo; type 2: 8% versus 4%., moderate. Repeated vomiting or inability to eat needs prompt review of fluids, glucose and insulin. (source)
  • Appetite loss: Type 1: 17% versus 2% placebo; type 2: 9% versus 2%., moderate. Eating less changes mealtime insulin needs; monitor intake and glucose together. (source)
  • Headache: Type 2 label pool: 13% versus 7% placebo., mild. Check glucose; persistent or severe headache needs assessment. (source)
  • Severe low blood sugar with insulin: Type 1, first 3 months without an initial insulin cut: medically assisted events in 7.3% versus 3.3% placebo., serious. Starting treatment requires your clinician to reduce mealtime insulin, with frequent blood sugar checks. (source)
  • Stomach pain: Type 2: 8% versus 7% placebo., moderate. Severe or persistent pain needs prompt assessment, especially with vomiting. (source)
  • Fatigue: Type 1 and type 2 label pools: 7% versus 4% placebo., mild (source)
  • Dizziness: Type 1: 5% versus 4% placebo; type 2: 6% versus 4%., moderate. Check glucose and avoid driving while symptoms persist. (source)
  • Injection-site reactions: Postmarketing reports; frequency cannot be estimated., mild. Use room-temperature solution, rotate sites and check injection technique. (source)
  • Pancreatitis: Reported after approval; frequency and causation are uncertain., serious. Severe persistent upper-abdominal pain, especially with vomiting, needs urgent assessment. (source)

Stop and get help if

  • Confusion, seizure, fainting, or low blood sugar that does not recover: Follow your prescribed rescue plan. Call emergency services for severe symptoms or failure to recover.
  • Severe persistent upper-belly pain, especially with vomiting: Stop pramlintide and seek urgent care for possible pancreatitis.
  • Swollen face or throat, trouble breathing, or widespread hives: Stop the injection and seek emergency care.
  • Repeated vomiting or inability to keep down food or fluids: Get urgent help with blood sugar, fluids and insulin. Do not inject pramlintide if you cannot eat.

Who should avoid it

  • under18: Pediatric safety and effectiveness are not established; the label advises against pediatric use.
  • pregnant: Human safety data are limited; rat studies found birth defects at high exposures.
  • breastfeeding: Transfer into human milk, infant effects and milk production are unknown.
  • tryingToConceive: Plan diabetes care with your clinician before pregnancy.
  • gastroparesis: The label rules out use with gastroparesis, meaning slow stomach emptying. Pramlintide slows it further.
  • other: The label rules out use if you cannot feel low blood sugar warning signs.
  • other: Avoid after severe low blood sugar needing help within the past 6 months, or when episodes recur.
  • other: The label rules out use after a serious allergy to pramlintide or any ingredient.
  • other: The label excludes people with HbA1c above 9%, unreliable glucose checks or inability to follow insulin adjustments. HbA1c measures long-term blood sugar.
  • eatingDisorderHistory: Appetite loss and nausea may worsen restrictive eating; this is not a label contraindication.
  • pancreatitisHistory: Pancreatitis has been reported after approval; prior pancreatitis needs review before use.
  • kidneyDisease: Kidney disease needs clinician review. No label dose change for creatinine clearance 15–89 mL/min. End-stage kidney disease has not been studied.
  • liverDisease: Liver impairment has not been studied.
  • surgeryPlanned: Fasting and illness affect dosing and insulin needs. If interrupted, the label requires restarting the initiation schedule.
  • other: Visual or hand-function problems can cause dosing errors; the label calls for extra caution.
  • other: Migraine-like attacks occurred in an IV provocation study. The risk with routine SC doses is not established.
  • diabetes: Pramlintide supplements insulin; it cannot replace it. Mealtime insulin must be adjusted with close glucose monitoring.
  • testedAthlete: No pramlintide-specific 2026 ruling was found. Confirm with the sport’s anti-doping body; accompanying insulin is prohibited.
  • other: The label excludes people who need medicines that stimulate gut movement.

Interactions

  • Insulin: Severe low blood sugar risk rises. When starting pramlintide, your clinician must reduce mealtime insulin and plan blood sugar checks. Inject separately; never mix.
  • Sulfonylureas and meglitinides: These increase insulin release and can add to low-glucose risk; reassess the glucose-lowering plan.
  • Time-sensitive oral medicines: For medicines needing rapid or threshold absorption, the label says at least 1 hour before or 2 hours after pramlintide.
  • Warfarin and other critical oral medicines: Stomach emptying is delayed. No specific warfarin interaction trial was found; review timing and condition-specific monitoring.
  • Medicines changing gut movement: The label advises against use with drugs that change gut movement or slow nutrient absorption.
  • GLP-1 and GIP/GLP-1 drugs: Fullness and delayed stomach emptying may add up. 3 cases with type 1 diabetes and obesity leave combination safety uncertain.
  • Other amylin agonists: Shared amylin effects may add nausea and slow stomach emptying. Cell studies do not establish combination safety.
  • Drugs that increase low-glucose risk: These medicines can raise low blood sugar risk when taken together.
  • Drugs that mask low-glucose symptoms: These can hide low blood sugar warning signs.
  • Metreleptin: Obesity trials tested this pair, but neutralizing leptin antibodies raised concern. The combination has no obesity approval.

Product quality risks

  • No independent study testing online pramlintide products or counterfeit Symlin pens was located.
  • Other online peptide tests show why identity, content and contamination matter; those rates cannot be assigned to pramlintide.
  • In three online semaglutide samples, purity was 7–14% and content 29–39% above the label; one contained elevated endotoxin. This was not pramlintide.
  • FDA warns that poor compounding can cause contamination or too much or too little active drug.
  • A research-use label and an HPLC purity number do not establish an injectable product’s sterility or dose.

How Pramlintide works

It copies amylin, a hormone released with insulin after meals. It slows food leaving the stomach, reduces the liver’s meal-related sugar signal and helps you feel full. Its short action is why Symlin is injected before meals.

  • Amylin receptors, AMY1–AMY3: Signals through calcitonin receptors paired with RAMP proteins.
  • Meal-related glucagon release: Reduces the signal telling the liver to release sugar after eating.
  • Stomach emptying and fullness: Slows food delivery to the gut and reduces meal size.

Half-life: About 48 minutes in healthy adults; label dose studies show 48–55 minutes.

Gaps: Long-term effects on death, heart events, kidney damage and diabetes complications are not established. Modern combinations with semaglutide or tirzepatide lack large randomized pramlintide trials. Community prevalence is unknown; small forum counts are not estimates of all users. No reliable non-seller source established powder vial sizes, water volumes, microdosing or cycling. The highest obesity dose here is 360 mcg BID or TID. Older brief safety studies used higher doses; this is not a general safety ceiling. Exact schedules and all arm-level outcomes remain unavailable for some old or unpublished trials. WADA, UK authorisation and Australian scheduling need further drug-specific confirmation. No independent online pramlintide quality survey or compound-specific poison-center series was located. Pramlintide and cagrilintide have separate dose evidence. No validated dose-conversion or head-to-head replacement schedule was found.

Related to Pramlintide

Pramlintide: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.